This Month in The Journal  by Bungartz, Kathryn D. & Williamson, Robin E.
EDITORS’ CORNER
This Month in The Journal
Kathryn D. Bungartz1 and Robin E. Williamson2Keeping It Together to Avoid Tearing It Apart
Prakash et al., page 743
Thoracic aortic aneurysms and dissections (TAAD) occur
when the walls of the aorta break down, enlarge, and can
eventually rupture. The good news about TAAD is that
surgery can fix the problem; the bad news is that there
are few, if any, ways to know that a problem exists before
it is too late. Most cases of TAAD are sporadic, but familial
cases do exist, and a number of loci have been identified. In
those families in which gene mutations have been identi-
fied, the disrupted genes are involved with the contractility
or the adhesion of smooth muscle cells. This has led to the
hypothesis that the disruption of such pathways is likely to
be associated with increased risk of TAAD. In this issue,
Prakash et al. perform genome-wide analyses to identify
copy-number variants (CNVs) that are significantly associ-
ated with increased risk of TAAD. The authors look for
CNVs that are enriched in their datasets of patients with
sporadic TAAD and familial TAAD. A number of loci are
implicated in their analysis, and their assessment of the
functions and pathways of the genes involved provide
additional support for the hypothesis that genes disrupted
in TAAD are involved in the maintenance of the extracel-
lular matrix, cell adhesion, and vascular smooth cell
contractility.I’ll Take Mine Rare
Liu and Leal, page 790
The SNP arrays used for genome-wide association analyses
(GWAS) contain common SNPs that can serve as proxies
for genomic regions, but very rare or unique variants are
not captured well. GWAS using these chips have identified
a number of disease risk alleles, but a large percentage of
heritability for these phenotypes remains to be identified.
One prediction is that rare variants contribute significantly
to disease risk and that these variants can only be identified
through the use of more comprehensive sequencing
approaches. Sequencing technologies are becoming time-
effective and cost-effective enough that it is now feasible
to do a large amount of sequencing, either entire genomes
or exomes or candidate regions, in tested individuals.
There are now several instances in which rare variants
that are significantly associated with disease risk have
been identified. With the increased use of methodology1Science Editor, AJHG; 2Deputy Editor, AJHG
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to establish the best ways to replicate and confirm these
associations. Is it best to resequence in an independent
set of cases and controls the entire gene that contains the
implicated variant in order to determine the total risk
load of rare variants in that gene? Or, is it sufficient to
genotoype the risk variant already identified in the addi-
tional samples? It is surely less expensive to do targeted
genotyping, but is that really a rigorous analysis of the
region’s rare variants that contribute to disease risk? In
this issue, Liu and Leal address these questions about
how best to assess the replication of associations with
rare variants. The authors incorporate information about
population genetics and sequencing error rates into their
analyses to establish recommendations for following up
on significant associations with rare variants.mtDNA Mutations Might Allow Detection
of Prostate Cancer
Kloss-Brandsta¨tter et al., page 802
Prostate cancer follows only skin cancer in the onerous
title of most common cancers affecting men. The prostate
is a gland that comprises part of the male reproductive
system. It is responsible for producing a portion of the
seminal fluid. Men with early stages of prostate cancer
often have no symptoms. Rather, an enlarged or abnormal
prostate is likely to be discovered during the digital rectal
exam (DRE), the classic ‘‘turn your head and cough’’
portion of a standard physical examination. Blood tests
for prostate-specific antigen (PSA) are also commonplace
for men over 40 or 50 years of age. Neither an abnormal
prostate gland nor an elevated level of PSA is diagnostic
for prostate cancer, but both indicate that further testing
is needed. Biopsies are used for actual diagnosis of the
cancer. Recognizing the important role that mitochondrial
DNA (mtDNA) mutations have been found to play in the
development and progression of many types of cancer, in
this issue Dr. Kloss-Brandsta¨tter and colleagues sequenced
the entire mitochondrial genome in prostate cancer
patients to find clues as to why so many men develop
the cancer. By examining both the frequency and types
of somatic mtDNA mutations in prostate cancer patients,
this team is able to identify several genetic changes having
clinical significance. Among their exciting findings is an
association between somatic tRNA mutations and PSAGenetics. All rights reserved.
Journal of Human Genetics 87, 737–738, December 10, 2010 737
levels at diagnosis. Although prostate cancer is treatable by
surgery, radiation, or chemotherapy, it is often fatal.
Finding genetic changes associated with prostate cancer
and its primary biomarker will potentially help monitor
and treat this common deadly disease.Proliferation Rate Matters
Stark et al., page 829
The HapMap populations have served as a tremendous
resource to researchers across the world. The international
project was initiated in an effort to help researchers iden-
tify genetic variants associated with human disease. In
Phase I of the project, samples were collected and geno-
typed from people from four different populations: Yoruba
in Ibadan, Nigeria (YRI); Japanese in Tokyo (JPT); Han
Chinese in Beijing (CHB); and CEPH (Utah residents
with European ancestry; CEU). The DNA for genotyping
these people came from Epstein-Barr-virus-transformed
lymphoblastoid cell lines (LCLs). These lines are main-
tained by the International HapMap Project and distrib-
uted to researchers as requested. Last year, the HapMap
populations expanded to include more members of these
four original populations, and samples from seven addi-
tional populations were also collected. Again, LCLs were
created and used for DNA extraction and genotyping.
And again, these LCLs are maintained and distributed.
Despite the unprecedented and largely altruistic informa-
tion provided by these cell lines, a paper in this week’s issue
advises caution when comparing data obtained from LCLs
arising from the first phase of the HapMap project with
those from HapMap Phase III. Stark and colleagues
compare the proliferation rate between LCLs of different
populations established at different times during the
HapMap Project. They find differences both between pop-
ulations and between lines from the same population
established a couple of years apart. These findings do not738 The American Journal of Human Genetics 87, 737–738, Decembin any way diminish the contribution of the International
HapMap Project, but they do highlight some potential
confounding issues regarding genetic studies using these
samples.Sometimes It’s the Men, and Sometimes
It’s the Women
Emery et al., page 848
There has been an ongoing discussion over whether
human evolution has been characterized by a female
bias, meaning that individual males mated with more
than one female, versus a male bias, in which one female
has offspring fathered by a number of different males.
Determining the human sex ratio through history has
traditionally depended on data from mtDNA and the Y
chromosome, but newer analyses using whole-genome
sequence data have had more power. They also disagree
with each other. Some report evidence of a female bias,
and others report a male bias. The studies presenting these
different views have used different methodologies on
different datasets, so it has been suspected that the contra-
diction in the results might be due to the different
approaches used. But, which studies were performed
correctly and got the right answer? In this issue, Emery
and colleagues report their analyses of the data and
conclude that, in a way, both sides are right. The authors
examine the same set of data with both methods and eval-
uate which factors affect the findings. It turns out that
when these sex biases occurred makes a difference; one
approach is more sensitive to recent biases, whereas the
other approach better detects ancestral bias. Emery et al.
propose that an ancestral female bias in all human popula-
tions and a subsequent male bias in non-African popula-
tions is consistent with the results obtained by previous
studies and can reconcile some of the reported conflicts.er 10, 2010
